Cargando…

Empagliflozin does not change cardiac index nor systemic vascular resistance but rapidly improves left ventricular filling pressure in patients with type 2 diabetes: a randomized controlled study

BACKGROUND: In the EMPA-REG OUTCOME trial (Empagliflozin Cardiovascular Outcome Event Trial) treatment with the sodium-glucose cotransporter-2 (SGLT2) inhibitor empagliflozin significantly reduced heart failure hospitalization (HHF) in patients with type 2 diabetes mellitus (T2D) and established car...

Descripción completa

Detalles Bibliográficos
Autores principales:	Rau, Matthias, Thiele, Kirsten, Hartmann, Niels-Ulrik Korbinian, Schuh, Alexander, Altiok, Ertunc, Möllmann, Julia, Keszei, András P., Böhm, Michael, Marx, Nikolaus, Lehrke, Michael
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2021
Materias:	Original Investigation
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7791833/ https://www.ncbi.nlm.nih.gov/pubmed/33413355 http://dx.doi.org/10.1186/s12933-020-01175-5

Ejemplares similares

Empagliflozin reduces markers of acute kidney injury in patients with acute decompensated heart failure
por: Thiele, Kirsten, et al.
Publicado: (2022)

Effects of empagliflozin on markers of calcium and phosphate homeostasis in patients with type 2 diabetes – Data from a randomized, placebo-controlled study
por: Rau, Matthias, et al.
Publicado: (2022)

Effects of COPD on Left Ventricular and Left Atrial Deformation in Patients with Acute Myocardial Infarction: Strain Analysis Using Speckle-Tracking Echocardiography
por: Grebe, Julian, et al.
Publicado: (2022)

Outcome of transcatheter edge-to-edge mitral valve repair in patients with diabetes mellitus: Results from a real-world cohort
por: Kirschfink, Annemarie, et al.
Publicado: (2022)

Distinct pressure half-time values by transthoracic echocardiography for grading of paravalvular regurgitation after transcatheter aortic valve replacement
por: Schröder, Joerg, et al.
Publicado: (2020)

Echocardiographic determination of right ventricular volumes and ejection fraction: Validation of a truncated cone and rhomboid pyramid formula
por: Al Ateah, Ghazi, et al.
Publicado: (2023)

Incidence and clinical relevance of persistent iatrogenic atrial septal defect after percutaneous mitral valve repair
por: Alachkar, Mhd Nawar, et al.
Publicado: (2021)

Evaluation of aortic root for definition of prosthesis size by magnetic resonance imaging and cardiac computed tomography: implications for transcatheter aortic valve implantation
por: Koos, Ralf, et al.
Publicado: (2011)

Dynamic handgrip exercise for the evaluation of mitral valve regurgitation: an echocardiographic study to identify exertion induced severe mitral regurgitation
por: Alachkar, Mhd Nawar, et al.
Publicado: (2020)

Empagliflozin Increases Cardiac Energy Production in Diabetes: Novel Translational Insights Into the Heart Failure Benefits of SGLT2 Inhibitors
por: Verma, Subodh, et al.
Publicado: (2018)

Human and mouse non‐targeted metabolomics identify 1,5‐anhydroglucitol as SGLT2‐dependent glycemic marker
por: Kappel, Ben A., et al.
Publicado: (2021)

The Cardio-Kidney Patient: Epidemiology, Clinical Characteristics and Therapy
por: Schuett, Katharina, et al.
Publicado: (2023)

The incretin hormone GIP is upregulated in patients with atherosclerosis and stabilizes plaques in ApoE(−/−) mice by blocking monocyte/macrophage activation
por: Kahles, Florian, et al.
Publicado: (2018)

High-Risk Cardiovascular Patients: Clinical Features, Comorbidities, and Interconnecting Mechanisms
por: Schuett, Katharina Andrea, et al.
Publicado: (2015)

Post-cardiac injury syndrome after transcatheter mitral valve repair using MitraClip system: a case report
por: Alachkar, Mhd Nawar, et al.
Publicado: (2020)

Effects of Transcatheter Mitral Valve Repair Using MitraClip(®) Device on Sleep Disordered Breathing in Patients with Mitral Valve Regurgitation
por: Daher, Ayham, et al.
Publicado: (2021)

Empagliflozin Reduces Interleukin-6 Levels in Patients with Heart Failure
por: Gotzmann, Michael, et al.
Publicado: (2023)

Impact of diabetes duration on left ventricular mass regression with empagliflozin
por: Moroney, Michael, et al.
Publicado: (2023)

Influence of rivaroxaban compared to vitamin K antagonist treatment upon development of cardiovascular calcification in patients with atrial fibrillation and/or pulmonary embolism
por: Stöhr, Robert, et al.
Publicado: (2022)

Positioning of NORs and NOR-bearing chromosomes in relation to nucleoli
por: Kalmárová, Markéta, et al.
Publicado: (2007)

Non‐targeted metabolomics identify polyamine metabolite acisoga as novel biomarker for reduced left ventricular function
por: Puetz, Andreas, et al.
Publicado: (2021)

Human multipotent hematopoietic progenitor cell expansion is neither supported in endothelial and endothelial/mesenchymal co-cultures nor in NSG mice
por: Radtke, Stefan, et al.
Publicado: (2019)

Interleukin-6 predicts inflammation-induced increase of Glucagon-like peptide-1 in humans in response to cardiac surgery with association to parameters of glucose metabolism
por: Lebherz, Corinna, et al.
Publicado: (2016)

Humankind neither nasty nor brutish
por: Marmot, Michael
Publicado: (2020)

The Role of Vitamin D(3) as an Independent Predicting Marker for One-Year Mortality in Patients with Acute Heart Failure
por: Thiele, Kirsten, et al.
Publicado: (2022)

Cardiopulmonary work up of patients with and without fatigue 6 months after COVID-19
por: Thiele, Kirsten, et al.
Publicado: (2022)

Effect of Empagliflozin on Cardiovascular and Renal Outcomes in Patients With Heart Failure by Baseline Diabetes Status: Results From the EMPEROR-Reduced Trial
por: Anker, Stefan D., et al.
Publicado: (2020)

Efficacy and Safety of Low-Dose Protamine in Reducing Bleeding Complications during TAVI: A Propensity-Matched Comparison
por: Kneizeh, Kinan, et al.
Publicado: (2023)

Glycaemic variability is associated with all-cause mortality in COVID-19 patients with ARDS, a retrospective subcohort study
por: Hartmann, Bojan, et al.
Publicado: (2022)

fastGapFill: efficient gap filling in metabolic networks
por: Thiele, Ines, et al.
Publicado: (2014)

Characteristics of Ventricular Electrophysiological Substrates in Metabolic Mice Treated with Empagliflozin
por: Jhuo, Shih-Jie, et al.
Publicado: (2021)

Inhibition of the norA gene expression and the NorA efflux pump by the tannic acid
por: Tintino, Saulo Relison, et al.
Publicado: (2023)

Peptide YY (PYY) Is Associated with Cardiovascular Risk in Patients with Acute Myocardial Infarction
por: Haj-Yehia, Elias, et al.
Publicado: (2020)

Neither Angel nor Beast
por: Coleman, Francis
Publicado: (2013)

Empagliflozin in type 1 diabetes
por: Mathieu, Chantal, et al.
Publicado: (2019)

Anti-inflammatory potential of Empagliflozin
por: Pirklbauer, Markus
Publicado: (2021)

Drug eruption associated with empagliflozin
por: Yau, Kevin, et al.
Publicado: (2022)

The gut hormone glucose-dependent insulinotropic polypeptide is downregulated in response to myocardial injury
por: Kahles, Florian, et al.
Publicado: (2022)

Empagliflozin reduces Ca/calmodulin‐dependent kinase II activity in isolated ventricular cardiomyocytes
por: Mustroph, Julian, et al.
Publicado: (2018)

The rDNA transcription machinery is assembled during mitosis in active NORs and absent in inactive NORs
Publicado: (1996)

Cannot write session to /tmp/vufind_sessions/sess_aqsqq4i5u5hnf03lqksok3be6g